JP7766605B2 - 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用 - Google Patents

非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用

Info

Publication number
JP7766605B2
JP7766605B2 JP2022547788A JP2022547788A JP7766605B2 JP 7766605 B2 JP7766605 B2 JP 7766605B2 JP 2022547788 A JP2022547788 A JP 2022547788A JP 2022547788 A JP2022547788 A JP 2022547788A JP 7766605 B2 JP7766605 B2 JP 7766605B2
Authority
JP
Japan
Prior art keywords
biomarker
subject
nash
minutes
aptamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022547788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512701A (ja
JP2023512701A5 (https=
Inventor
リー アレキサンダー
レイチェル オストロフ
スチュアート フィールド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of JP2023512701A publication Critical patent/JP2023512701A/ja
Publication of JP2023512701A5 publication Critical patent/JP2023512701A5/ja
Priority to JP2025181395A priority Critical patent/JP2026021411A/ja
Application granted granted Critical
Publication of JP7766605B2 publication Critical patent/JP7766605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022547788A 2020-02-10 2021-02-09 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用 Active JP7766605B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025181395A JP2026021411A (ja) 2020-02-10 2025-10-28 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972418P 2020-02-10 2020-02-10
US62/972,418 2020-02-10
PCT/US2021/017217 WO2021163034A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025181395A Division JP2026021411A (ja) 2020-02-10 2025-10-28 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用

Publications (3)

Publication Number Publication Date
JP2023512701A JP2023512701A (ja) 2023-03-28
JP2023512701A5 JP2023512701A5 (https=) 2024-01-30
JP7766605B2 true JP7766605B2 (ja) 2025-11-10

Family

ID=74858782

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547788A Active JP7766605B2 (ja) 2020-02-10 2021-02-09 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用
JP2025181395A Pending JP2026021411A (ja) 2020-02-10 2025-10-28 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025181395A Pending JP2026021411A (ja) 2020-02-10 2025-10-28 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用

Country Status (12)

Country Link
US (1) US20230071234A1 (https=)
EP (1) EP4103948A1 (https=)
JP (2) JP7766605B2 (https=)
KR (1) KR20220140727A (https=)
CN (1) CN115066616A (https=)
AU (1) AU2021220787A1 (https=)
BR (1) BR112022015303A2 (https=)
CA (2) CA3300793A1 (https=)
IL (1) IL295064A (https=)
MX (1) MX2022009517A (https=)
PH (1) PH12022552003A1 (https=)
WO (1) WO2021163034A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238881A1 (ja) * 2022-06-07 2023-12-14 日東電工株式会社 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー
WO2025090996A1 (en) * 2023-10-28 2025-05-01 Novelna Inc. Nafld detection proteins and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180016638A1 (en) 2015-02-03 2018-01-18 The Trustees Of The University Of Pennsylvania Novel methods for early identification of bone healing ability in injured patients
WO2019018610A1 (en) 2017-07-19 2019-01-24 Bio-Rad Europe Gmbh COMBINATIONS OF BIOMARKERS FOR THE SIMULTANEOUS EVALUATION OF A NON ALCOHOLIC STHEATOHEPATITIS AND A STATE OF HEPATIC FIBROSIS

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7824871B2 (en) * 2007-06-14 2010-11-02 George Mason Intellectual Properties Methods of diagnosing non-alcoholic steatohepatitis (NASH)
CN101802225B (zh) 2007-07-17 2013-10-30 私募蛋白质体公司 检测样品的多元分析
JP5781436B2 (ja) * 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
CN103429753A (zh) 2010-09-27 2013-12-04 私募蛋白质体公司 间皮瘤生物标记及其用途
WO2014150198A2 (en) * 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
EP3110976B1 (en) * 2014-02-27 2020-05-13 Biogen MA Inc. Method of assessing risk of pml
EP3303629A1 (en) * 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
KR20180029046A (ko) * 2015-06-19 2018-03-19 세라 프로그노스틱스 인코포레이티드 조산 예측용 바이오마커 쌍
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
US20210215711A1 (en) * 2016-02-08 2021-07-15 Somalogic, Inc. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180016638A1 (en) 2015-02-03 2018-01-18 The Trustees Of The University Of Pennsylvania Novel methods for early identification of bone healing ability in injured patients
WO2019018610A1 (en) 2017-07-19 2019-01-24 Bio-Rad Europe Gmbh COMBINATIONS OF BIOMARKERS FOR THE SIMULTANEOUS EVALUATION OF A NON ALCOHOLIC STHEATOHEPATITIS AND A STATE OF HEPATIC FIBROSIS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KE, Meng-yun，Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma，J Transl Med.，2019年05月02日，17(1):140，pp.1-10，doi: 10.1186/s12967-019-1889-0

Also Published As

Publication number Publication date
CA3166923A1 (en) 2021-08-19
JP2023512701A (ja) 2023-03-28
IL295064A (en) 2022-09-01
US20230071234A1 (en) 2023-03-09
KR20220140727A (ko) 2022-10-18
PH12022552003A1 (en) 2024-02-05
AU2021220787A1 (en) 2022-09-01
CN115066616A (zh) 2022-09-16
BR112022015303A2 (pt) 2022-09-27
JP2026021411A (ja) 2026-02-10
WO2021163034A1 (en) 2021-08-19
EP4103948A1 (en) 2022-12-21
CA3300793A1 (en) 2026-03-02
MX2022009517A (es) 2022-09-02

Similar Documents

Publication Publication Date Title
US10359435B2 (en) Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof
CN116008563B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
JP2026021411A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用
JP7792338B2 (ja) 耐糖能異常障害を決定する方法
JP2025516097A (ja) 試料品質評価の方法
JP2025526256A (ja) 試料品質評価の方法
JP2025516095A (ja) 試料品質評価の方法
JP2025516096A (ja) 試料品質評価の方法
JP2025516098A (ja) 試料品質評価の方法
JP2025505923A (ja) 試料品質評価の方法
JP2023546563A (ja) 心血管イベントリスクの予測
HK40026777B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK40078108A (en) Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK40026777A (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1246853B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1246853A1 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1259917A1 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1259917B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1220251B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251028

R150 Certificate of patent or registration of utility model

Ref document number: 7766605

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150